The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced ...

The GARDP Foundation and Debiopharm have entered a collaboration and license agreement to pursue the development of a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae.

New options for testing and treating some of the most common sexually transmitted diseases are becoming available ...

Debio1453 is a first-in-class antibiotic candidate that targets an enzyme that’s essential for the growth of Neisseria ...

Last year, the US authorities approved the first at-home test that can detect three common infections in women — gonorrhea, ...

A deadly, drug-resistant fungus has infected more than 7,000 people across 27 U.S. states, including Mississippi, in 2025, ...

Dealing with an infection isn't as straightforward as simply killing the pathogen. The body also needs to carefully steer and ...

Candida auris is a drug-resistant fungus that spreads mainly in health care settings, including nursing homes and hospitals.

Researchers report how Paenibacillus avoids harm by its own antibiotic — information that is crucial for developing new drug ...